加味逍遥汤合并氯米帕明治疗抑郁症的对照研究

目的观察加味逍遥汤合并氯米帕明与单用氯米帕明治疗抑郁症的临床疗效。方法将105例抑郁症患者随机分为两组。治疗组53例抑郁症患者中医辨证为郁证（肝气郁结型），用加味逍遥汤合并氯米帕明25～50mg／d治疗。对照组52例单用氯米帕明75～225mg／d治疗。共治疗8周为1个疗程。采用汉密尔顿抑郁量表（HAMD）分别对两组治疗前，治疗后2、4、8周用量表评分，总体印象量表（CGI）观察两组疗效，以及副反应量表（TESS）评定不良反应。结果HAMD评分及CGI—SI评分两组治疗后8周与治疗前比较差异均有显著性（P〈0．01）；两组治疗后比较差异无显著性（P〉0．05）。治疗组不良反应以口干、便秘为主，对照组不良反应以口干、便秘、头晕、失眠、视力模糊、Q—T间期延长为主，治疗组不良反应明显低于对照组（P〈0．01）。结论加味逍遥汤合并氯米帕明治疗抑郁症与单用氯米帕明疗效相当，且安全，不良反应轻。

Study on Modified Xiaoyao Decoction Combining Clomipamine in Treating Depression

Objective To observe the efficacy of Modified Xiaoyao Decoction (MXD) combining clomipramine in treatment of depression. Methods One hundred and five depression patients were randomly assigned to two groups. The treated group (53 patients), all were differentiated as Gan-qi stagnation syndrome type and treated with MXD combining clomipramine 25-50 mg/d. The control group (52 patients) treated with clomipramine 75-225 mg/d alone. The treatment lasted for 8 weeks in both groups. Scores of depression was assessed with Hamilton Depression Scale (HAMD) before treatment and at the 2nd, 4th,8th week of the treatment, efficacy and adverse reactions were evaluated with Global Impression of Change (CGI) and Treatment Emergent Symptom Scale (TESS) respectively. Results After treatment the scores in both groups were significantly different from those before treatment (P<0.01), but no significant difference was found between the two groups (P>0.05). Main adverse reactions were dry mouth, constipation in the treated group, much less than those in the control group, which were mainly dry mouth, constipation, dizziness, insomnia, blurred vision and prolonged Q-T interval (P<0.01). Conclusion MXD combining clomipramine has the efficacy on depression similar to clomipramine, but has less adverse reactions.